World-leading pathologist Associate Professor Michael Tetzlaff visits MIA
20 December 2018
Melanoma Institute Australia (MIA) is proud to have one of the world’s leading pathologists, Associate Professor Michael Tetzlaff, with us for this past week.
A/Prof Tetzlaff hails from the Department of Pathology and Translational and Molecular Pathology at the MD Anderson Cancer Centre at The University of Texas.
Spending his time with fellow pathologist Professor Richard Scolyer, MIA’s Co-Medical Director, and his team at Royal Prince Alfred Hospital, A/Prof Tetzlaff is sharing his pathological expertise in primary mucosal melanoma and merkel cell carcinoma, and assisting in the assessment of pathological samples from patients undergoing neoadjuvant, targeted therapy.
Among over 100 published peer-reviewed articles, A/Prof Tetzlaff is also lead author on a paper recently published by the International Neoadjuvant Melanoma Consortium that aims to standardise the pathologic evaluation of resected melanoma metastases following neoadjuvant-targeted or immune-checkpoint therapy.
It is an honour to have Associate Professor Tetzlaff as an international collaborator, and we are delighted to be hosting him on his first ever trip to Australia.
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.